Janson C, Platz JH, Soulard S, Langham S, Nicholson L, Hartgers-Gubbels ES. Reducing carbon footprint by switching to reusable soft mist inhalers. ERJ Open Res 2023;9(3):00543-2022.

Pooley N, Abdool Karim SS, Combadière B, Ooi EE, Harris RC, El Guerche Seblain C, et al. Durability of vaccine-induced and natural immunity against COVID-19: a narrative review. Infect Dis Ther 2023:1-21.

Wright A, Vioix H, de Silva S, Langham S, Cook J, Capstick T, et al. Cost–consequence analysis of COPD treatment according to NICE and GOLD recommendations compared with current clinical practice in the UK. BMJ Open 2022;12(6):e059158.

Sethi S, Wright A, Hartgers-Gubbels E, Hechtner M, Clark B, Wright C, et al. Costs and clinical consequences of compliance with COPD GOLD recommendations or national guidelines compared with current clinical practice in Belgium, Germany, Sweden, and the United States. Int J Chron Obstruct Pulmon Dis 2022;17:2149-2160.

Wright C, Misso K, Green R, Marjenberg Z. Rapid evidence publication in the COVID-19 era: impact on study quality and study identification (SA43). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022

Janson C, Hernando Platz J, Soulard S, Langham S, Nicholson L, Hartgers-Gubbels E. Reusable soft mist inhalers have an improved carbon footprint compared with dry powder inhalers and pressurised metered-dose inhalers (HSD2). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022

Janson C, Hernando Platz J, Soulard S, Langham S, Nicholson L, Hartgers-Gubbels E. Treatment with dual and triple therapy in chronic obstructive pulmonary disease in line with current guidelines reduces the carbon footprint (MT40). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022

Müllerová H, Marshall J, de Nigris E, Varghese P, Pooley N, Embleton N, et al. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis. Ther Adv Respir Dis 2022;16:17534666221113647.

Cottin V, Teague R, Nicholson L, Langham S, Baldwin M. The burden of progressive-fibrosing interstitial lung diseases. Front Med 2022;9:7999912

Cook J, Bloom C, Lewis J, Marjenberg Z, Hernando Platz J, Langham S. Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease. J Mark Access Health Policy 2021;9(1):1929757

Vioix H, Wright A, de Silva S, Langham S, Gayle A, Soto J, Cook J, Capstick T, Quint J. PRS18 The clinical and cost impact of adherence to chronic obstructive pulmonary disease guideline recommendations in England- a cost consequence model. Value Health 2020;23(Suppl 2):S719

Langham S, Lewis J, Pooley N, Embleton N, Langham J. A systematic review of single-inhaler triple therapy in patients with chronic obstructive pulmonary disease (COPD). Value Health 2019;22(Suppl 3):S873

Langham S, Lewis J, Pooley N, Embleton N, Langham J, Han MK, Chalmers JD. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic and descriptive review. Respir Res 2019;20(1):242